Paper14990649
Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy.
Yeo W and 11 others. J Clin Oncol, 2004. Cited by 211 papers, by iCite.
Cite this record
ConductScience Library. Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy. Papers, record 14990649. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/14990649
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics27
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Hepatitis B | Major topic |
| Hepatitis B Surface Antigens | Major topic |
| Hepatitis B virus | Major topic |
| Lamivudine | Major topic |
| Neoplasms | Major topic |
| Adult | |
| Age Distribution | |
| Aged | |
| Carrier State | |
| Dose-Response Relationship, Drug | |
| Drug Administration Schedule | |
| Female | |
| Humans | |
| Incidence | |
| Male | |
| Middle Aged | |
| Neoplasm Staging | |
| Primary Prevention | |
| Probability | |
| Prognosis | |
| Reference Values | |
| Risk Assessment | |
| Secondary Prevention | |
| Serologic Tests | |
| Sex Distribution | |
| Survival Analysis | |
| Treatment Outcome |
Source PubMed
Cited by78
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 211 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 38958900 | Cross-sectional study of hepatitis B virus infection in female breast cancer patients in China for the first time diagnosed. | Clin Transl Oncol | 2025 | https://conductscience.org/library/papers/38958900 | PubMed |
| 37731995 | Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies in the targeted therapy era. | World J Gastroenterol | 2023 | https://conductscience.org/library/papers/37731995 | PubMed |
| 37463687 | Efficacy of Antiviral Prophylaxis up to 6 or 12 Months From Completion of Rituximab in Resolved Hepatitis B Patients: A Multicenter, Randomized Study. | J Korean Med Sci | 2023 | https://conductscience.org/library/papers/37463687 | PubMed |
| 36072805 | Effect of infection with hepatitis B virus on the survival outcome of diffuse large B-cell lymphoma in the prophylactic antiviral era. | Front Oncol | 2022 | https://conductscience.org/library/papers/36072805 | PubMed |
| 35478052 | Clinical usefulness of a novel high-sensitivity hepatitis B core-related antigen assay to determine the initiation of treatment for HBV reactivation. | J Gastroenterol | 2022 | https://conductscience.org/library/papers/35478052 | PubMed |
| 35430783 | KASL clinical practice guidelines for management of chronic hepatitis B. | Clin Mol Hepatol | 2022 | https://conductscience.org/library/papers/35430783 | PubMed |
| 34427860 | APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapy. | Hepatol Int | 2021 | https://conductscience.org/library/papers/34427860 | PubMed |
| 33576088 | Prophylactic antiviral therapy for hepatitis B virus surface antigen-positive patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy. | Cancer Sci | 2021 | https://conductscience.org/library/papers/33576088 | PubMed |
| 32729014 | Comparison of Tenofovir Disoproxil Fumarate and Entecavir in the Prophylaxis of HBV Reactivation. | Dig Dis Sci | 2021 | https://conductscience.org/library/papers/32729014 | PubMed |
| 32013312 | Prevention and management of viral hepatitis in inflammatory bowel disease: a clinical practice guideline by the Korean Association for the Study of Intestinal Diseases. | Intest Res | 2020 | https://conductscience.org/library/papers/32013312 | PubMed |
| 31752356 | Reactivation of Hepatitis B Virus in Patients with Multiple Myeloma. | Cancers (Basel) | 2019 | https://conductscience.org/library/papers/31752356 | PubMed |
| 31540124 | Hematological Malignancies and HBV Reactivation Risk: Suggestions for Clinical Management. | Viruses | 2019 | https://conductscience.org/library/papers/31540124 | PubMed |
| 31526114 | Analysis of Hepatitis B Virus Reactivation After Radiotherapy in Patients With Hepatocellular Carcinoma Using the Lyman NTCP Model. | Technol Cancer Res Treat | 2019 | https://conductscience.org/library/papers/31526114 | PubMed |
| 31290069 | Prediction and clinical implications of HBV reactivation in lymphoma patients with resolved HBV infection: focus on anti-HBs and anti-HBc antibody titers. | Hepatol Int | 2019 | https://conductscience.org/library/papers/31290069 | PubMed |
| 31185710 | KASL clinical practice guidelines for management of chronic hepatitis B. | Clin Mol Hepatol | 2019 | https://conductscience.org/library/papers/31185710 | PubMed |
| 31040945 | Defining and grading HBV reactivation. | Clin Liver Dis (Hoboken) | 2015 | https://conductscience.org/library/papers/31040945 | PubMed |
| 29977329 | Negative effect of hepatitis in overall and progression-free survival among patients with diffuse large B-cell lymphoma. | Infect Agent Cancer | 2018 | https://conductscience.org/library/papers/29977329 | PubMed |
| 29606020 | Hepatitis B Reactivation in the Treatment of Non-Hodgkin Lymphoma. | Cancer Control | 2018 | https://conductscience.org/library/papers/29606020 | PubMed |
| 28717701 | Cost Effectiveness of Universal Hepatitis B Virus Screening in Patients Beginning Chemotherapy for Sarcomas or GI Stromal Tumors. | J Glob Oncol | 2016 | https://conductscience.org/library/papers/28717701 | PubMed |
| 28219691 | Hepatitis B Reactivation Associated With Immune Suppressive and Biological Modifier Therapies: Current Concepts, Management Strategies, and Future Directions. | Gastroenterology | 2017 | https://conductscience.org/library/papers/28219691 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/14990649
GET https://conductscience.org/api/papers/v1/14990649/cited_by?page=2